Matthew Campbell

Matthew Campbell is a Senior Professor at The University of Texas MD Anderson Cancer Center. His research focuses on genitourinary oncology, encompassing kidney cancer, urothelial carcinoma, and germ cell tumors, with particular emphasis on cancer immunotherapy, pharmacology, and systemic treatment strategies. His recent work includes investigating somatic transformations in germ cell tumors, characterizing brain metastases in small cell carcinoma of the bladder, and evaluating antibody-drug conjugates such as disitamab vedotin for HER2-expressing advanced urothelial carcinoma. He has led clinical trials combining immune checkpoint inhibitors with debulking surgery in metastatic renal cell carcinoma, explored metastasis-directed radiotherapy for oligometastatic clear-cell disease, and assessed nivolumab plus ipilimumab in variant histology renal cell carcinoma. His publications appear in The Lancet Oncology, Nature Communications, and the Journal of Clinical Oncology.